Valneva
Created in 2013
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
8,486 41,238Activities
Technologies
Entity types
Location
6 Rue Alain Bombard, 44800 Saint-Herblain, France
Saint-Herblain
France
Employees
Scale: 501-1000
Estimated: 661
SIREN
422497560Engaged corporates
24
11 6Added in Motherbase
4 years, 2 months ago
biotech Value proposition
Specialty vaccine company focused on prevention of infectious diseases with major unmet need, such as Lyme & chikungunya
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 700 employees.
vaccinesOriginal language
Specialty vaccine company focused on prevention of infectious diseases with major unmet need, such as Lyme & chikungunya
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world’s first and only chikungunya vaccine, as well as certain third-party vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. with approximately 700 employees.
Home - Valneva
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
https://valneva.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 GSK Pharmaceutical, Pharmaceutical Manufacturing | GSK Pharmaceutical, Pharmaceutical Manufacturing | Not capitalistic Partnership Not event 30 Nov 2023 | | |
 Atlanpole Biotherapies Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Atlanpole Biotherapies Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 3 Oct 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Not capitalistic Not partnership Event 25 Jun 2019 | | |
 Atlanpole Business Consulting and Services | Atlanpole Business Consulting and Services | Other 19 Jan 2021 8 Jul 2024 | | |